Today: 7 February 2026
Subscribe
Browse Category

NYSE:MRK News 21 January 2026 - 31 January 2026

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck stock rises as markets wobble — what to watch before the Feb. 3 earnings call

Merck shares rose 1.2% to $109.64 Friday afternoon, outperforming a falling S&P 500. Health care stocks attracted buyers as inflation data came in hotter than expected and Donald Trump named Kevin Warsh as Federal Reserve chair. Investors are watching for Merck’s Feb. 3 earnings call, with focus on 2026 guidance and Keytruda sales trends.
30 January 2026
···
Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
···
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·····
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
··
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
··
Dow Jones rebounds as Trump rules out force on Greenland; tariffs still hang over Wall Street

Dow Jones rebounds as Trump rules out force on Greenland; tariffs still hang over Wall Street

The Dow Jones rose about 0.6% Wednesday, recovering nearly 297 points after President Trump ruled out using force to acquire Greenland. Tuesday saw the index plunge 870 points following new U.S. tariffs on European goods. Merck and UnitedHealth led early gains, while IBM and 3M dragged on the previous session. Investors await jobless claims data Thursday and the Fed meeting next week.
21 January 2026
······
Dow Jones rebounds after Tuesday’s 870-point hit as Trump cools Greenland talk

Dow Jones rebounds after Tuesday’s 870-point hit as Trump cools Greenland talk

The Dow Jones rose 203 points to 48,692.15 early Wednesday, rebounding after Tuesday’s 870-point drop triggered by Trump’s tariff threats on eight European countries. Healthcare stocks led gains, with Merck and UnitedHealth adding about 40 points. The Supreme Court began hearing arguments on Trump’s bid to fire Fed Governor Lisa Cook. A Reuters poll showed economists expect the Fed to hold rates steady this quarter.
21 January 2026
·······
1 2 3 4 … 9

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop